Objective: Multiple myeloma is still one of the incurable hematologic cancers. It
is a common problem of all hematologists to look for new combinations in this malignancy,
that treatment steps are rapidly depleted.
Method: The
cytotoxic activities of carfilzomib, lenalidomide and their combination with
ibrutinib were evaluated using the XTT colorimetric assay on U266B1/BR cells.
Cells were seeded into 96-well plates at a density of 1×104 cells
per well, incubated with various concentrations of ibrutinib, carfilzomib,
lenalidomide and their combinations for 24h and 48h.
Results: In our
study, we found that adding ibrutinib to carfilzomib and lenalidomide
combination in Bortezomib refractory myeloma cell line did not increase
cytotoxicity.
Conclusions: Further clinical and experimental studies are needed
to demonstrate the efficacy of ibrutinib in which many B-cell malignancy has
been demonstrated.
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Medical Science Research Makaleler |
Yazarlar | |
Yayımlanma Tarihi | 31 Aralık 2019 |
Kabul Tarihi | 31 Aralık 2019 |
Yayımlandığı Sayı | Yıl 2019Cilt: 41 Sayı: 4 |